BioAffinity Technologies (BIAF) announced it has received notification of allowance from the China National Intellectual Property Administration for a patent application related to its methods for predicting the likelihood of lung cancer using flow cytometry. The company said the patent, titled “System and Method for Determining Lung Health,” protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum. The patent is related to the company’s CyPath Lung diagnostic test.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- BioAffinity Technologies gets China patent for siRNA-based cancer therapy
- bioAffinity Receives Nasdaq Non-Compliance Notice
- BioAffinity gets U.S. patent for novel broad spectrum cancer therapies
- bioAffinity Technologies Enters Sales Agreement with WallachBeth
- BioAffinity Technologies appoints Dr. Gordon Downie as Chief Medical Officer